Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 24;15(1):21. doi: 10.3390/ph15010021

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

ATV protected K18-hACE2-transgenic mice infected with SARS-CoV-2 from mortality. The survival (A), and weight variation (B) of the different experimental groups: non-infected and non-treated (MOCK) or SARS-CoV-2-infected and non-treated (NIL) SARS-CoV-2-infected and treated with ATV. After 12h of infection the treated group received the first of a daily dose of 60 mg/kg of ATV. The animals were treated for six days. Survival was statistically assessed by Log-rank (Mentel–Cox) test, where * p < 0.05. The viral load (C), LDH levels (D), polymorphonuclear and mononuclear cells counts (E) and immunocytochemical staining (F) were assessed in the BAL six days after infection in the indicated experimental groups. All the analysis were performed with 6 mice/group.